Trevi Therapeutics, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Trevi Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $162.35M, a 51.18% increase year-over-year.
- Trevi Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2025-12-31 was $20.00K.
- Trevi Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $0.00.
- Trevi Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $107.39M.
- Trevi Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2025 was $107.41M, a 129.67% increase from fiscal 2024.
- Trevi Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2024 was $46.77M.
- Trevi Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2021 was $7.09M, a 134.00% increase from fiscal 2020.
- Trevi Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2020 was $3.03M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $162.35M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $20.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $107.41M 10-K · filed 2026-03-17 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | |
| 2025-06-30 | $107.39M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $5.00K 10-Q · filed 2026-05-05 | |
| 2024-12-31 | $46.77M 10-K · filed 2026-03-17 | |
| 2022-03-31 | -$22.00K 10-Q · filed 2022-05-12 | $3.02M derived: sum of 4 quarters · filed 2022-05-12 |
| 2021-12-31 | -$28.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $7.09M 10-K · filed 2022-03-17 |
| 2021-09-30 | $359.00K 10-Q · filed 2021-11-10 | $7.79M derived: sum of 4 quarters · filed 2022-05-12 |
| 2021-06-30 | $2.71M 10-Q · filed 2021-08-12 | $9.80M derived: sum of 4 quarters · filed 2022-05-12 |
| 2021-03-31 | $4.06M 10-Q · filed 2022-05-12 | |
| 2020-12-31 | $668.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $3.03M 10-K · filed 2022-03-17 |
| 2020-09-30 | $2.36M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |